文献速递炎症性肠病

溃疡性结肠炎/克罗恩病患者生物制剂转换时机与感染风险:一项回顾性研究

Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis/Crohn's Disease: A Retrospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-04-09

本研究基于Optum去标识化Clinformatics Data Mart数据库,纳入2017年9月1日至2022年8月31日新启动生物制剂治疗的11992例成人UC/CD患者,其中1293例发生生物制剂转换,64.2%为重叠转换。调整后分析显示,重叠转换与非重叠转换在任一感染和严重感染风险上均无显著差异。

要点

  • 1293例发生生物制剂转换的患者中,64.2%为重叠转换(OS)。
  • 重叠转换与非重叠转换的任一感染调整后风险无显著差异(aHR 1.40,P = .17)。
  • 重叠转换与非重叠转换的严重感染调整后风险无显著差异(aHR 0.95,P = .93)。

核心结论

  • 重叠转换在真实世界中常见,与非重叠转换相比未增加严重感染风险。
  • 缩短洗脱期可能对患者安全性风险极小,同时改善UC/CD治疗管理和试验招募。

研究设计与样本

  • 回顾性观察性研究,使用Optum去标识化Clinformatics Data Mart数据库。
  • 纳入2017年9月1日至2022年8月31日新启动生物制剂治疗的11992例成人UC/CD患者。
  • 1293例发生生物制剂转换,其中64.2%为重叠转换(OS,停用初始生物制剂后≤5个半衰期内转换至另一生物制剂)。
  • 非重叠转换(NOS)定义为停用初始生物制剂后>5个半衰期转换至另一生物制剂。
  • 采用逆概率治疗加权Cox比例风险模型估计调整风险比(aHR)。

主要发现

  • 任一感染的调整后发病率(每1000人年)在转换组间相当。
  • 任一感染:OS vs NOS的aHR为1.40(P = .17),无显著差异。
  • 严重感染:OS vs NOS的aHR为0.95(P = .93),无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is limited evidence on real-world patterns and safety of biologic switch timing in patients with ulcerative colitis (UC)/Crohn's disease (CD). This study investigated biologic therapy switch occurrence in real-world practice and compared the risk of any infection and serious infection between patients with overlapping (OS) vs non-overlapping switches (NOS). METHODS: This retrospective observational study identified patients with UC/CD initiating biologic therapy between September 1, 2017, and August 31, 2022, in Optum's de-identified Clinformatics Data Mart Database. Crude incidence rates (IRs) per 1000 person-years (PYs) and timing of switch were assessed. Biologic switch events were categorized as OS (switch to another biologic within ≤5 half-lives after discontinuation of initial biologic) or NOS (switch to another biologic >5 half-lives after discontinuation of initial biologic). Inverse probability of treatment weighted Cox proportional hazards modeling estimated adjusted hazard ratios (aHRs) of any infection and serious infection associated with switch timing. RESULTS: Among 11,992 adult patients newly initiating a biologic therapy for UC/CD, 1293 patients underwent a biologic switch, 64.2% of which were considered an OS. Adjusted IRs per 1000 PYs, for any infection, were comparable across switching groups. No significant differences in the aHRs of infections were found between OS and NOS (any infection: aHR, 1.40; P = .17; serious infection: aHR, 0.95; P = .93). CONCLUSIONS: OSs were common and not associated with an increased risk of serious infection vs non-overlapping biologics. Shortened washout periods may pose minimal safety risks to patients while improving UC/CD therapy management and improving trial recruitment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kruger AJ, Dormont F, Capit N, et al. Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis/Crohn's Disease: A Retrospective Study. Clin Gastroenterol Hepatol. 2025. PMID: 40204205. doi:10.1016/j.cgh.2025.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。